Abstract: The present invention is related to the use of 2,3 substituted pyrazine sulfonamides of formula (I) for the treatment and/or prevention of allergic diseases, inflammatory dermatoses and other diseases with an inflammatory component. Specifically, the present invention is related to the use of 2,3 substituted pyrazine sulfonamides for the modulation, notably the inhibition, of CRTH2 activity.

Abstract: Techniques for optimizing a software application include receiving, at a local computing system, a query from an application for data stored on a database table, the query including a context defined by a name of the database table; comparing the context of the query to a context of a predefined query scenario; based on the context of the query matching the context of the predefined query scenario, retrieving data stored on a secondary database replicated from data stored on a main database; and passing the retrieved data from the secondary database to the application.

Abstract: Methods, systems, and apparatus, including computer program products, for implementing a software architecture design for a software application implementing service request and order management. The application is structured as multiple process components interacting with each other through service interfaces, and multiple service interface operations, each being implemented for a respective process component. The process components include an Outbound Delivery process component, a Site Logistics Processing process component, a Confirmation and Inventory process component, a Customer Requirement Processing process component, a Supply and Demand Matching process component, a Logistics Execution Control process component, a Service Request Processing process component, a Customer Quote Processing process component, a Service Order Processing process component, a Service Contract process component, and a Service Confirmation Processing process component.

Abstract: The invention provides novel, substituted 3-arylamino pyridine compounds pharmaceutically acceptable salts, solvates and prodrug compounds thereof, wherein W, R1, R2, R9, R10, R11, R12, R13, R14 are as defined in the specification. Such compounds are MEK inhibitors and useful in the treatment of hyperproliferative diseases, such as cancer, restenosis and inflammation. Also disclosed is the use of such compounds in the treatment of hyperproliferative diseases in mammals, especially humans, and pharmaceutical compositions containing such compounds.

Abstract: A method for supporting a configuration of an interface is provided, wherein the configuration environment has an overview region that has several subregions. At least one item of information concerning a part of the configuration is displayed in each subregion. For each subregion, an item of information concerning the part of the configuration associated with the subregion is displayed. In the case of a warning and/or error message, a configuration option is displayed so as to be selectable, via which the warning/error message is resolved. The selection of the displayed configuration option causes a functionality to be started via which the displayed configuration option is made possible. In the case of a change in the status of a subregion, the display of the status and/or warning and/or error message and a configuration option derived therefrom in one subregion or several subregions is automatically updated and adapted to the changed status.

Abstract: Methods, systems, and apparatus, including computer program products, for implementing a software architecture design for a software application implementing service request and order management. The application is structured as multiple process components interacting with each other through service interfaces, and multiple service operations, each being implemented for a respective process component. The process components include an Outbound Delivery process component, a Site Logistics Processing process component, an Inventory Processing process component, a Customer Requirement Processing process component, a Supply and Demand Matching process component, a Logistics Execution Control process component, a Service Request Processing process component, a Service Order Processing process component, and a Service Confirmation Processing process component.

Abstract: Techniques for optimizing a software application include receiving, at a local computing system, a query from an application for data stored on a database table, the query including a context defined by a name of the database table; comparing the context of the query to a context of a predefined query scenario; based on the context of the query matching the context of the predefined query scenario, retrieving data stored on a secondary database replicated from data stored on a main database; and passing the retrieved data from the secondary database to the application.

Abstract: The invention provides novel, substituted 3-arylamino pyridine compounds pharmaceutically acceptable salts, solvates and prodrug compounds thereof, wherein W, R1, R2, R9, R10, R11, R12, R13, R14 are as defined in the specification. Such compounds are MEK inhibitors and useful in the treatment of hyperproliferative diseases, such as cancer, restenosis and inflammation. Also disclosed is the use of such compounds in the treatment of hyperproliferative diseases in mammals, especially humans, and pharmaceutical compositions containing such compounds.

Abstract: The invention provides 2-carboxamide piperazine compounds, and methods of treatment and pharmaceutical compositions that utilize or comprise one or more such compounds. Compounds of the invention are useful for the treatment of mammalian infertility.

Abstract: The present invention is related to thiazolidine carboxamide derivatives of formula (II) for the treatment and/or prophylaxis of preterm labor, premature birth, dysmenorrhea and for stopping labor prior to cesarean delivery.

Abstract: The present invention is related to piperazine-2-carboxamide derivatives of formula (I) for the treatment and/or prophylaxis of preterm labor, premature birth, dysmenorrhea and for stopping labor prior to cesarean delivery. Wherein A, X, Y, R1 and R2 are as defined in the description.

Abstract: The invention relates to compounds of formula (I): wherein X, W, Q, R, R1 and R2 have the meanings given in claim 1. The compounds are useful, for example, in the treatment of autoimmune disorders, such as multiple sclerosis.

Abstract: The present disclosure describes methods, systems, and computer program products for analyzing historic changes to business objects. One method includes monitoring at least one business object for a modification made to at least one business object node attribute. In response to a monitored modification associated with a particular business object node attribute, a new historical version of the at least one business object node attribute is prepared, the new historical version of the at least one business object node attribute including the modified business object node attribute value. A previous historical version of the at least one business object node attribute is retrieved and updated in response to the monitored modification. The new historical version of the at least one business object node attribute and the updated previous historical version of the at least one business object node attribute are then stored.

Abstract: The invention provides novel, substituted 3-arylamino pyridine compounds pharmaceutically acceptable salts, solvates and prodrug compounds thereof, wherein W, R1, R2, R9, R10, R11, R12, R13, R14 are as defined in the specification. Such compounds are MEK inhibitors and useful in the treatment of hyperproliferative diseases, such as cancer, restenosis and inflammation. Also disclosed is the use of such compounds in the treatment of hyperproliferative diseases in mammals, especially humans, and pharmaceutical compositions containing such compounds.

Abstract: The present invention is related to a novel series of pyrimidyl or fused pyrimidyl hydrazones. Compounds of Formula (I) wherein A is selected from the group consisting of Formulas (A1), (A2), (A3), (A4), (A5) are useful for the treatment and/or prevention of a proliferative disease.

Abstract: The present invention is related to a novel series of pyrimidyl or fused pyrimidyl hydrazones. Compounds of Formula (I) wherein A is selected from the group consisting of Formulas (A1), (A2), (A3), (A4), (A5) are useful for the treatment and/or prevention of a proliferative disease.

Abstract: The present invention is related to the use of spiro derivatives of Formula (I) for the treatment and/or prevention of allergic diseases, inflammatory dermatoses and other diseases with an inflammatory component. Specifically, the present invention is related to the use of spiro derivatives for the modulation of CRTH2 activity.

Abstract: The invention relates to compounds of formula I: wherein R1, R2,Ra, Rb, X have the meanings given in claim 16. The compounds are useful e.g. in the treatment of autoimmune disorders, such as multiple sclerosis.

Abstract: The invention provides novel, substituted 3-arylamino pyridine compounds pharmaceutically acceptable salts, solvates and prodrug compounds thereof, wherein W, R1, R2, R9, R10, R11, R12, R13, R14 are as defined in the specification. Such compounds are MEK inhibitors and useful in the treatment of hyperproliferative diseases, such as cancer, restenosis and inflammation. Also disclosed is the use of such compounds in the treatment of hyperproliferative diseases in mammals, especially humans, and pharmaceutical compositions containing such compounds.

Abstract: The invention relates to compounds of formula (I) wherein R1, R2, X1, X2, Y, Ra, Rb, Q have the meanings given in claim 1. The compounds are useful e.g. in the treatment of autoimmune disorders, such as multiple sclerosis and also in the treatment of cancer disorders.